Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–87 of 87 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Acne Vulgaris Clear all
Active, not recruiting Phase 2 Interventional Results available

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT03827798
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Clearwater, Florida • Orange Park, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 12, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

NCT03852472
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa
Interventions
Avacopan, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
91
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 12, 2026, 1:03 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 12, 2026, 1:03 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

NCT07287644
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
BFB759, Placebo for BFB759
Biological · Other
Lead sponsor
Bluefin Biomedicine, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
31
States / cities
Phoenix, Arizona • Encino, California • Santa Monica, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 12, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242498
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
24
States / cities
Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 12, 2026, 1:03 PM EDT
Completed No phase listed Observational

Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment

NCT01727440
View directory record Official record
Conditions
Acne Vulgaris, Isotretinoin
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
12 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
6
States / cities
Concord, North Carolina • Davidson, North Carolina • Harrisburg, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 12, 2026, 1:03 PM EDT
Completed Not applicable Interventional

Feasibility Study: Ulthera® System for the Treatment of Moderate to Severe Facial Acne

NCT01591304
View directory record Official record
Conditions
Facial Acne
Interventions
Ulthera System Treatment
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Woodland Hills, California • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 12, 2026, 1:03 PM EDT
Completed Phase 2 Interventional

BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

NCT01241331
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BLI1100, Vehicle cream
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
12 Years to 45 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
20
States / cities
Fremont, California • Los Angeles, California • Oceanside, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 12, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Results available

ABSORICA in Patients With Severe Recalcitrant Nodular Acne

NCT02457520
View directory record Official record
Conditions
Acne
Interventions
Isotretinoin
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
12 Years to 45 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 12, 2026, 1:03 PM EDT
Active, not recruiting Not applicable Interventional

Study on Using Radiofrequency to Treat Moderate to Severe Acne

NCT06315166
View directory record Official record
Conditions
Moderate to Severe Acne Vulgaris
Interventions
triLift/Legend Pro+ Fractional RF System
Device
Lead sponsor
Pollogen
Industry
Eligibility
18 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Grosse Pointe, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 12, 2026, 1:03 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
61
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 12, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne

NCT00706433
View directory record Official record
Conditions
Acne Vulgaris
Interventions
aminolevulinic acid HCL (ALA), Vehicle (VEH)
Drug · Other
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2011 · Synced Oct 12, 2026, 1:03 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT05620836
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
38
States / cities
Scottsdale, Arizona • Arkansas City, Arkansas • Fayetteville, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 12, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Combination Treatment for Moderate to Severe Acne

NCT01206348
View directory record Official record
Conditions
Acne
Interventions
Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
12 Years to 30 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
10
States / cities
Birmingham, Alabama • Santa Monica, California • Hockessin, Delaware + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 12, 2026, 1:03 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris

NCT02796066
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Vehicle, TSN2898
Drug
Lead sponsor
Thesan Pharmaceuticals, Inc.
Industry
Eligibility
16 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
4
States / cities
San Diego, California • Miami, Florida • High Point, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 12, 2026, 1:03 PM EDT